More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests "The breadth of data at ASCO GU ...
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...
Paired Central and Peripheral Blood Cultures for Febrile Neutropenia in Pediatric Patients With Cancer: Do We Need Peripheral Blood Cultures? Their investigation was a study imbedded in a randomized ...
TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...
A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results